跳转至内容
Merck
CN
  • Pasireotide is more effective than octreotide, alone or combined with everolimus on human meningioma

Pasireotide is more effective than octreotide, alone or combined with everolimus on human meningioma

Oncotarget (2017-09-15)
Thomas Graillon, David Romano, Céline Defilles, Christophe Lisbonis, Alexandru Saveanu, Dominique Figarella-Branger, Pierre-Hugues Roche, Stéphane Fuentes, Olivier Chinot, Henry Dufour, Anne Barlier
摘要

Pasireotide is a somatostatin analog (SSA) that targets somatostatin receptor subtype 1 (SST1), SST2, SST3, and SST5 with a high affinity. Pasireotide has a better antisecretory effect in acromegaly, Cushing's disease, and neuroendocrine tumors than octreotide. In this study, we compared the effects of pasireotide to those of octreotide

材料
货号
品牌
产品描述

Sigma-Aldrich
MISSION® esiRNA, targeting human EIF4EBP1